The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index; none of the 15 sources its claims cite is checked for support yet.
State policies regulating short-term limited duration insurance plans and cancer stage at diagnosis
Open accessAbstract
Short-term limited duration insurance plans, which proliferated following 2018 federal regulations, may not provide adequate protections for patients with suspected or newly diagnosed cancer and can destabilize insurance markets for comprehensive insurance plan enrollees. Individuals aged 18-64 years with newly diagnosed cancer from 11 states during 2016-2017 and 2019 were identified from the Surveillance, Epidemiology, and End Results program. Difference-in-differences analyses were used to compare changes in early-stage cancer diagnoses from 2016-2017 to 2019 in states that prohibited vs did not regulate short-term limited duration insurance plans. In adjusted difference-in-differences analyses, early-stage diagnoses increased 0.95 percentage points (95% confidence interval = 0.53 to 1.38, P < .001) in states that prohibited short-term limited duration insurance plans vs did not regulate short-term limited duration insurance plans. State policies resulting in unavailability of short-term limited duration insurance plans were associated with an increased percentage of early-stage diagnoses.
Overview
CoChat Summary
TL;DR
In difference-in-differences analyses of SEER data from 11 states, state policies prohibiting short-term limited duration insurance plans were associated with a 0.95 percentage-point increase in early-stage cancer diagnoses from 2016-2017 to 2019 compared with states with no such regulation. This translated to approximately 650 more early-stage diagnoses in 2019 in prohibiting states.
Key findings
- Adjusted difference-in-differences analyses showed early-stage diagnoses increased 0.95 percentage points (95% CI = 0.53 to 1.38, P < .001) in states that prohibited short-term limited duration insurance plans vs states that did not regulate them, translating to approximately 650 more early-stage diagnoses in 2019.
- States with other short-term limited duration insurance policies had less change (−0.71 percentage points, 95% CI = −1.92 to 0.50, P = .25).
- Relative to states where short-term limited duration insurance plans remained available, early-stage diagnoses increased 0.77 percentage points (95% CI = 0.00 to 1.53, P = .05) in states where legislation stopped the sale of such plans; after excluding states with Medicaid eligibility changes, the increase was 1.03 percentage points (95% CI = 0.71 to 1.35, P < .001), translating to more than 800 more early-stage diagnoses.
- Results were similar for potentially screening-detectable cancers and other cancers, and falsification tests in individuals aged 65 years and older showed no statistically significant changes in cancer stage by state short-term limited duration insurance status.
Methods
- Difference-in-differences analysis using Surveillance, Epidemiology, and End Results registry data from 11 states covering 26.5% of the US population.
- Included 398,190 individuals aged 18-64 years with staged first primary malignancies diagnosed 2016-2019; pre-period was 2016-2017, post-period was 2019, and 2018 was excluded as a washout and phase-in period.
- Linear probability models accounted for state clustering and adjusted for age, race, ethnicity, sex, metropolitan residence status, marital status, county household income, cancer site, and state and year fixed effects; sensitivity analyses excluded states with Medicaid eligibility changes, and subgroup analyses examined screening-detectable and other cancers.
Limitations
- The paper states the study is retrospective, and many states enacted other policies during the period that could affect the health insurance market and care delivery and confound findings.
- The paper states the study was limited to 11 SEER states, which may not be representative, and had only 1-year follow-up after short-term limited duration insurance expansion, so long-term impacts are unclear.
- The paper states individual insurance plan data are lacking, and it is unclear whether individuals who otherwise would be uninsured might benefit from short-term limited duration insurance plans, though the difference-in-differences results suggest a net harm.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures

Verification
Claims the paper makes
0 Valid · 0 Not valid · 9 Not checked · 24 Own results and interpretations
A result the paper states — it cites no source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“translating to more than 800 more early-stage diagnoses”
§ State policies regulating short-term limited duration insurance plans and cancer stage at diagnosis > Abstract
plainstates a causen = 190 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“with less change in states with other short-term limited duration insurance policies (−0.71 percentage points, 95% CI = −1.92 to 0.50, P = .25)”
- Also stated in: § Abstract · plain
“However, limited legislation regulating but still enabling sale of short-term limited duration insurance plans was not associated with changes in the percentage of early-stage diagnoses.”
§ State policies regulating short-term limited duration insurance plans and cancer stage at diagnosis > Abstract
plainn = 190- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
- Also stated in: § Abstract · plain
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“(after excluding states with Medicaid eligibility changes: 1.03 percentage points, 95% CI = 0.71 to 1.35, P < .001)”
§ State policies regulating short-term limited duration insurance plans and cancer stage at diagnosis > Abstract
plainstates a causen = 190 ·- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Rests on an assumption not shown here.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“Results were similar for potentially screening-detectable cancers and other cancers (Supplementary Table 4, available online).”
§ State policies regulating short-term limited duration insurance plans and cancer stage at diagnosis > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
A result the paper reports from its own data — it cites no other source for it, so there is none to check. The quote shows it is in the paper.
In the paper
“There were no statistically significant changes in cancer stage by state short-term limited duration insurance status in falsification tests (Supplementary Table 6, available online).”
§ State policies regulating short-term limited duration insurance plans and cancer stage at diagnosis > Abstract
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
14 more claims
Create a free account to see all 33 claims and to verify the 7 references still open.
- It may state two separate claims as one. 7
- Probably not a substantial claim. 8
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Findings were consistent among cancer types with recommend screening tests (ie, female breast and colorectal cancers) and extended prior research conducted in a limited number of states, underscoring the importance of state policies and federal efforts to limit STLD plans.11,12”
From Short-Term Limited Duration Insurance Plan Policies and Cancer Stage at Diagnosis (2025) · cites this paper as [11]
In the citing paper
“While we accounted for state-specific variation that could affect cancer diagnosis stage by including a state random effect in multivariable models, there were various other health and public policies enacted over the study period that could affect insurance coverage and/or access to care that could also influence our findings.11”
From Short-Term Limited Duration Insurance Plan Policies and Cancer Stage at Diagnosis (2025) · cites this paper as [11]
Citations
Cites
Methods for Evaluating Changes in Health Care Policy: The Difference-in-Differences Approach
Dimick, J. B., & Ryan, A. M. (2014) · JAMA · doi:10.1001/jama.2014.16153 · Cited by 1,193
Short-term health insurance plans come up short for patients with cancer
Barnes, J. M., & Chino, F. (2022) · JAMA Oncology · doi:10.1001/jamaoncol.2022.1624 · Cited by 8
Self-citation
Cited by
High-Deductible Health Plans and Mortality Among Cancer Survivors
Barnes, J. M., Gupta, A., Ragavan, M. V., Santos, P. M., Wallingford, S., & Chino, F. L. (2026) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.56451 · Cited by 2
Self-citationAnalysis Of The Use Of Digital Technology In Insurance Premium Management
Nur, D. L., & Nasution, M. I. P. (2023) · Moneta Journal of Economics and Finance · doi:10.61978/moneta.v2i1.118 · Cited by 2
Short-Term Limited Duration Insurance Plan Policies and Cancer Stage at Diagnosis
Yang, N. N., Zhao, J., Barnes, J. M., Kirchhoff, A. C., Chino, F., Yabroff, K. R., & Han, X. (2025) · JAMA Network Open · doi:10.1001/jamanetworkopen.2025.1075 · Cited by 1
Self-citationAhmad, Z. N., Lopez, P. L. V., Bliss, C. C., Kirchhoff, A. C., Durieux, N. M., Foor, A., Mitchell, C. O., Ponzani, C. J., Berghuijs, K. M. V. T., Waters, A. R., et al. (2026) · Journal of Health Psychology · doi:10.1177/13591053261460712 · Cited by 1
Self-citationZhao, J., Graetz, I., Howard, D., Yabroff, K. R., & Lipscomb, J. (2026) · Cancer · doi:10.1002/cncr.70190
Self-citation
Metadata
- Authors
- Barnes, J. M., Kirchhoff, A. C., Yabroff, K. R., & Chino, F.
- Affiliations
- Washington University in St. Louis (US)
- University of Utah (US)
- American Cancer Society (US)
- Memorial Sloan Kettering Cancer Center (US)
- Corresponding author
- Barnes, Justin M
- Venue
- JNCI Cancer Spectrum
- Publisher
- Oxford University Press (OUP)
- Published
- 2023-08-12
- Volume
- 7
- Issue
- 5
- ISSN
- 2515-5091 (ISSN-L)
- PMC
- PMC10471520
- OpenAlex
- W4385791107
- Cited by
- 5
- References
- 2
- Citations by year
- 2026: 3 · 2025: 1 · 2023: 1
- FWCI
- 0.73
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Licence
- Locations
- JNCI Cancer Spectrum (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Funders
- American Cancer Society
- American Society of Clinical Oncology
- National Cancer Institute (P30CA008748)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Healthcare Policy and Management
- Health Sciences › Medicine › Oncology › Global Cancer Incidence and Screening
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Economic and Financial Impacts of Cancer
- Keywords
- state insurance regulation, cancer stage at diagnosis, early-stage cancer, newly diagnosed cancer, cancer screening
- MeSH terms
- Humans, Insurance, Neoplasm Staging, Neoplasms, United States
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
A language model drew the claims from the paper on 2026-11-18, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-11-18 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: State policies regulating short-term limited duration insurance plans and cancer stage at diagnosis. https://app.cochat.ai/papers/10.1093/jncics/pkad060
- The paper
- Barnes, J. M., Kirchhoff, A. C., Yabroff, K. R., & Chino, F. (2023). State policies regulating short-term limited duration insurance plans and cancer stage at diagnosis. JNCI Cancer Spectrum. https://doi.org/10.1093/jncics/pkad060
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.